Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-05-05 DOI:10.1158/2643-3230.BCD-25-0071

Jordan S Goldstein, Nick A Phillips, Ash A Alizadeh

引用次数: 0

Abstract

In this issue of Blood Cancer Discovery, Pomeroy and Palmer present a new mathematical model, incorporating both inter- and intra-patient heterogeneity, to accurately predict outcomes for first-line combination therapies in diffuse large B-cell lymphoma. Their quantitative framework opens a range of possibilities for optimizing trial design and lymphoma therapy with potential to expedite clinical development. See related article by Pomeroy and Palmer, p. 254.

查看原文本刊更多论文

超越试验和错误：一个数学模型争论DLBCL的异质性，以优化联合治疗。

在这一期的《血癌发现》中，Pomeroy和Palmer提出了一个新的数学模型，结合了患者间和患者内部的异质性，以准确预测弥漫性大b细胞淋巴瘤一线联合治疗的结果。他们的定量框架为优化试验设计和淋巴瘤治疗开辟了一系列可能性，有可能加快临床发展。参见波默罗伊和帕尔默的相关文章，第254页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.